BNP Paribas Financial Markets Acquires Shares of 9,719 SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

BNP Paribas Financial Markets purchased a new stake in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 9,719 shares of the company's stock, valued at approximately $351,000.

Other large investors have also made changes to their positions in the company. Barclays PLC grew its stake in shares of SpringWorks Therapeutics by 60.4% during the 3rd quarter. Barclays PLC now owns 155,676 shares of the company's stock valued at $4,987,000 after acquiring an additional 58,645 shares during the period. Park Avenue Securities LLC bought a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at approximately $203,000. SG Americas Securities LLC bought a new position in shares of SpringWorks Therapeutics during the 4th quarter valued at approximately $210,000. KBC Group NV grew its stake in shares of SpringWorks Therapeutics by 59.1% during the 4th quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after acquiring an additional 978 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of SpringWorks Therapeutics by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,773 shares of the company's stock valued at $570,000 after acquiring an additional 1,488 shares during the period.

Analyst Ratings Changes

SWTX has been the subject of a number of recent research reports. Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a research note on Tuesday, April 29th. Wedbush reissued a "neutral" rating and issued a $47.00 price target (down from $81.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Barclays reissued an "equal weight" rating and issued a $47.00 price target (down from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. TD Cowen reissued a "hold" rating and issued a $47.00 price target (down from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Finally, HC Wainwright reissued a "neutral" rating and issued a $47.00 price target (down from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Seven investment analysts have rated the stock with a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $52.57.

SpringWorks Therapeutics Stock Performance

Shares of SWTX traded up $0.04 during mid-day trading on Friday, hitting $46.72. 4,425,623 shares of the stock were exchanged, compared to its average volume of 2,229,325. The company has a market cap of $3.52 billion, a PE ratio of -13.43 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00. The firm has a 50-day moving average of $43.28 and a two-hundred day moving average of $43.21.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.30). The firm had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. On average, sell-side analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

Insider Transactions at SpringWorks Therapeutics

In other news, COO Badreddin Edris sold 20,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the transaction, the chief operating officer now owns 169,712 shares of the company's stock, valued at approximately $9,203,481.76. The trade was a 10.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Saqib Islam sold 49,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $54.24, for a total value of $2,657,760.00. Following the transaction, the chief executive officer now directly owns 954,869 shares in the company, valued at approximately $51,792,094.56. This represents a 4.88% decrease in their position. The disclosure for this sale can be found here. Insiders own 7.83% of the company's stock.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.